Stockwatch

TAAT Global Alternatives Inc
Symbol	TAAT
Shares Issued	114,951,655
Close 2023-06-22	C$ 0.17
Market Cap	C$ 19,541,781
Recent Sedar+ Documents

TAAT enters consulting deal for advisory services

2023-06-22 16:41 ET - News Release

Subject: Taat Global Alternatives Inc. Word Document File: '\\swfile\EmailIn\20230622 132447 Attachment 2023-06-22 - New Release.docx' TAAT(TM) Global Alternatives Inc. Announces Consulting Agreement LAS VEGAS and VANCOUVER, JUNE 22, 2023 - TAAT(TM) GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the "Company" or "TAAT(TM)") announces that it has entered into a consulting agreement dated June 15, 2023 (the "Agreement") with an arm's length party (the "Consultant") to provide certain business liaison and strategic opportunity advisory services to the Company (the "Services"). The term of the Agreement with the Consultant is for a period of one year pursuant to which the Company will pay the Consultant a monthly fee of $10,000 plus tax. Pursuant to the Agreement, the Company has also agreed to issue the Consultant $100,000 plus tax worth of common shares (the "Shares"), which will be issued over the course of the first six months of the Agreement. A total of 610,810 Shares will be issued to the Consultant at a price of $0.185 per Share with 1/6th of the Shares being released to the Consultant each month. The Agreement may be terminated by either party, by giving the other party thirty (30) days' notice. Upon termination of the Agreement, no further Services are required by the Consultant as at the termination date and no monies will be payable by the Company other than unpaid monthly fees or the Shares accrued at the effective date of termination. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus and Registration Exemptions ("NI 45-106"), the Shares will be issued pursuant to section 2.24 of NI 45-106 and will not be subject to statutory hold period of 4 months plus a day. The Company anticipates issuing the Shares on June 29, 2023. The Company also announces that pursuant to the news release dated June 8, 2023, it has issued an aggregate of 6,250,000 Shares at price of $0.185 per Share as payment of a termination fee with a Consultant of the Company. The Shares have a statutory hold period which will expire on October 16, 2023. On behalf of the Board of Directors of the Company, TAAT(TM) GLOBAL ALTERNATIVES INC. "Michael Saxon" Michael Saxon, CEO and Director For further information, please contact: TAAT(TM) Investor Relations 1-833-TAAT-USA (1-833-822-8872) investor@taatglobal.com THE CANADIAN SECURITIES EXCHANGE ("CSE") HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE'S REGULATION SERVICES PROVIDER. About TAAT(TM) Global Alternatives Inc. TAAT(TM) is a vertically integrated consumer product and distribution company, generating more than CAD $90 million in overall gross revenue annually. TAAT(TM) is strategically expanding its product categories including tobacco and reduced-risk alternatives, hemp, kratom, and other emerging CPG segments. TAAT(TM) has facilities to include a processing plant in Nevada as well as a distribution centre in Canton, Ohio, leveraging existing retail shelf space and pipelines into national wholesale channels. For more information, please visit http://taatglobal.com. Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the anticipated performance of TAAT(TM) in the tobacco industry. The forward-looking information reflects management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; (iii) changes to the regulatory landscape applicable to the Company's business; and (iv) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company's management to predict all risk factors, nor can the Company assess the impact of all factors on Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company's products will vary from person to person. No claims or guarantees can be made as to the effects of the Company's products on an individual's health and well-being. The Company's products are not intended to diagnose, treat, cure, or prevent any disease. This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees. Statement Regarding Third-Party Investor Relations Firms Disclosures relating to investor relations firms retained by TAAT(TM) Global Alternatives Inc. can be found under the Company's profile on http://sedar.com.